Royal Bank of Canada
APGE

Royal Bank of Canada’s Apogee Therapeutics APGE Stock Holding History

Royal Bank of Canada’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$408K Buy
3,074
+2,863
+1,357% +$258K ﹤0.01% 4521
2026
Q1 		$18K Sell
211
-927
-81% -$67.3K ﹤0.01% 5932
2025
Q4 		$85K Sell
1,138
-2,882
-72% -$182K ﹤0.01% 5281
2025
Q3 		$160K Buy
4,020
+3,935
+4,629% +$150K ﹤0.01% 5227
2025
Q2 		$4K Buy
85
+36
+73% +$1.37K ﹤0.01% 6669
2025
Q1 		$2K Sell
49
-727
-94% -$28.1K ﹤0.01% 6546
2024
Q4 		$35K Sell
776
-3,628
-82% -$185K ﹤0.01% 5858
2024
Q3 		$259K Buy
4,404
+1,002
+29% +$48K ﹤0.01% 4607
2024
Q2 		$134K Buy
3,402
+1,834
+117% +$89K ﹤0.01% 5070
2024
Q1 		$105K Sell
1,568
-4,841
-76% -$211K ﹤0.01% 5158
2023
Q4 		$179K Buy
6,409
+3,486
+119% +$69.9K ﹤0.01% 5192
2023
Q3 		$63K Buy
+2,923
New +$64.4K ﹤0.01% 5645

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Royal Bank of Canada's APGE Position: Q2 2026 in Review

Royal Bank of Canada increased its Apogee Therapeutics (APGE) stake by 1,357% in Q2 2026, buying an estimated $258K and bringing the position to 3,074 shares worth $408K. The position accounts for ﹤0.01% of the portfolio, ranked #4521.

Royal Bank of Canada first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Royal Bank of Canada held 3,074 shares of Apogee Therapeutics worth $408K as of Q2 2026.
  • Royal Bank of Canada bought 2,863 Apogee Therapeutics shares in Q2 2026, an estimated $258K.
  • Apogee Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #4521 holding.
  • Royal Bank of Canada first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.